Skip to main content
Erschienen in: Supportive Care in Cancer 6/2018

21.12.2017 | Original Article

Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey

verfasst von: S. Carnio, D. Galetta, V. Scotti, D. L. Cortinovis, A. Antonuzzo, S. Pisconti, A. Rossi, O. Martelli, F. L. Cecere, A. Lunghi, A. Del Conte, E. S. Montagna, J. Topulli, D. Pelizzoni, S. G. Rapetti, M. Gianetta, M. V. Pacchiana, V. Pegoraro, N. Cataldo, E. Bria, S. Novello

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Chemotherapy-induced nausea and vomiting (CINV) still represents a common side-effect of chemotherapy, and often, its perception differs between patients and healthcare professionals. The aim of this study was to evaluate the agreement on the perception of CINV and other items among clinicians, patients, and nurses.

Methods

This observational prospective study was part of an evaluation program promoted by the Women Against Lung Cancer in Europe (WALCE) Onlus. From August 2015 to February 2016, a survey was administered in 11 oncologic institutions to 188 stage IV lung cancer patients and to their oncologists and nurses during first-line chemotherapy. Our survey investigated 11 aspects: anxiety, mood, weakness, appetite, nausea, vomiting, pain, drowsiness, breath, general condition, and trust in treatments. These items were assessed through Numerical Rating Scale at four consecutive evaluations: at T0 (immediately prior to the first cycle), at T1 (immediately prior to the second cycle), at T2 (immediately prior to the third cycle), and at T3 (immediately prior to the fourth cycle). Clinician versus patient (CvP), nurse versus patient (NvP), and clinician versus nurse (CvN) agreements were estimated applying Weighted Cohen’s kappa. A multivariate logistic model and generalized equation estimates were applied to evaluate factors possibly influencing CINV development.

Results

The incidence of patients reporting CINV varied from 40% at T0 to 71% at T3. Both CvP and NvP agreement on the investigated items were mainly moderate, slightly increasing over time, and becoming substantial for some items, in particular for NvP. Pre-chemotherapy anxiety in its mild, moderate, and severe manifestations, as well as mild, moderate, and severe anxiety experienced after chemotherapy start, exposed patients to a higher risk of anticipatory and acute/delayed CINV, respectively.

Conclusions

Despite clinical staff awareness of patients’ status and perceptions, CINV still represents a clinical problem. This study confirms that particular attention should be paid to anxiety due to its key role in CINV development.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thödtmann J, Lordick F (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15(3):526–536. https://doi.org/10.1093/annonc/mdh110 CrossRefPubMed Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thödtmann J, Lordick F (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15(3):526–536. https://​doi.​org/​10.​1093/​annonc/​mdh110 CrossRefPubMed
7.
Zurück zum Zitat Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) American Society of Clinical OncologyAntiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198. https://doi.org/10.1200/JCO.2010.34.4614 CrossRefPubMedPubMedCentral Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) American Society of Clinical OncologyAntiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198. https://​doi.​org/​10.​1200/​JCO.​2010.​34.​4614 CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, de Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33(8):910–915. https://doi.org/10.1200/JCO.2014.57.9334 CrossRefPubMed Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, de Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33(8):910–915. https://​doi.​org/​10.​1200/​JCO.​2014.​57.​9334 CrossRefPubMed
13.
Zurück zum Zitat Chow R, Chiu L, Navari R, Passik S, Chiu N, Popovic M, Lam H, Pasetka M, Chow E, DeAngelis C (2016) Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer 24(2):1001–1008. https://doi.org/10.1007/s00520-015-3000-6 CrossRefPubMed Chow R, Chiu L, Navari R, Passik S, Chiu N, Popovic M, Lam H, Pasetka M, Chow E, DeAngelis C (2016) Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer 24(2):1001–1008. https://​doi.​org/​10.​1007/​s00520-015-3000-6 CrossRefPubMed
16.
19.
Zurück zum Zitat Basch E, Deal AM, Dueck AC et al (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197–198CrossRefPubMedPubMedCentral Basch E, Deal AM, Dueck AC et al (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197–198CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Basch E (2017) Patient-reported outcomes—harnessing patients’ voices to improve clinical care. N Engl J Med 376(2):105–108CrossRefPubMed Basch E (2017) Patient-reported outcomes—harnessing patients’ voices to improve clinical care. N Engl J Med 376(2):105–108CrossRefPubMed
Metadaten
Titel
Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey
verfasst von
S. Carnio
D. Galetta
V. Scotti
D. L. Cortinovis
A. Antonuzzo
S. Pisconti
A. Rossi
O. Martelli
F. L. Cecere
A. Lunghi
A. Del Conte
E. S. Montagna
J. Topulli
D. Pelizzoni
S. G. Rapetti
M. Gianetta
M. V. Pacchiana
V. Pegoraro
N. Cataldo
E. Bria
S. Novello
Publikationsdatum
21.12.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-4004-1

Weitere Artikel der Ausgabe 6/2018

Supportive Care in Cancer 6/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.